CELZ Stock Catalyst: Creative Medical Technology Completes Enrollment and Treatment in FDA-Cleared ADAPT Trial

Aug 20, 2026 · 9:16am ET

The trial is moving to follow-up and Phase 3 planning.

Max move

+33.0%

High of day $1.49

Sparker timei

9:16am ET

CELZ · Aug 20, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Creative Medical Technology Holdings, Inc. (Nasdaq: CELZ) has completed enrollment and treatment across the entire FDA-cleared ADAPT trial for Olastrocel in chronic lower back pain, including the opioid expansion cohort. The trial is now moving to follow-up and Phase 3 planning.

The company has a free float of 2,384,644 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time CELZ sparks.

Download Sniper App →

Catch the next CELZ-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →